GENEDRIVE PLC — Regulatory Filings 2021

Feb 17, 2021

National Storage Mechanism | Additional information

RNS Number : 3999P

Genedrive PLC

17 February 2021

REACH

genedrive plc

("genedrive" or the "Company")

First shipments to US of Genedrive® 96 SARS-CoV-2 Kit

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces the first shipments to the United States of its Genedrive® 96 SARS-CoV-2 Kits.

Following the Company's announcement on 28 January 2021 confirming genedrive's distribution agreement with Beckman Coulter Life Sciences ("Beckman Coulter"), genedrive can confirm that it has completed its commercial and technical training with the Beckman Coulter sales representatives and has now shipped its first 96 SARS-CoV-2 Kits to the USA. This shipment will allow Beckman Coulter to commence initial sales activities and prepare the market for wider commercial rollout. This shipment coincides with the formal launch of the Genedrive® 96 SARS-CoV-2 Kit by Beckman Coulter today.

To learn more about the partnership or to request a quote, Beckman Coulter customers can visit: 

https://www.beckman.com/reagents/genomic/viral-detection/genedrive-96-sars-cov-2

David Budd, CEO of genedrive plc, said: "This is an important milestone for genedrive as the first shipments of our Genedrive 96 SAR-CoV-2 kit are exported to the US. We are very optimistic about the US market for Covid PCR testing and it has market drivers that are favorable to the adoption of the genedrive assay: efficiency, ease of use, automation friendly, and scalability."

For further details please contact:

genedrive plc	+44 (0)161 989 0245
David Budd: CEO / Matthew Fowler: CFO
Peel Hunt LLP (Nominated Adviser and Joint Broker)	+44 (0)20 7418 8900
James Steel / Oliver Jackson
finnCap (Joint Broker)	+44 (0)20 7220 0500
Geoff Nash / Kate Bannatyne / Alice Lane
Walbrook PR Ltd (Media & Investor Relations)	+44 (0)20 7933 8780 or genedrive@walbrookpr.com
Paul McManus / Anna Dunphy	+44 (0)7980 541 893 / +44 (0)7876 741 001

About genedrive plc (http://www.genedriveplc.com)

genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRASFASMWEFSEIE